What Are the Risks of NOT Using Hormone Therapy?

Ask about the risks of HRT and you will get a detailed answer - breast cancer, blood clots, stroke, all carefully enumerated. We wrote that article ourselves: the risks of HRT.

But decisions have two columns, and the second one almost never gets filled in. Declining estrogen affects your bones, heart, brain, and tissues whether or not you treat it - which means not using hormone therapy is also an active choice with consequences. Here is what belongs in that column.

One thing this article is not: an argument that everyone must take HRT. Plenty of women sail through menopause with mild symptoms, and effective non-hormonal alternatives exist for nearly every problem below. This is about seeing the whole ledger before you decide - because "do nothing" is the one option that rarely gets a risk briefing.

Bone loss: the quiet one

Estrogen is your skeleton's maintenance signal. When it falls at menopause, the balance between bone building and bone breakdown tips - hard:

• Women lose up to 10% of bone mass in the first five years after menopause, the steepest decline of adult life.
• Roughly 1 in 2 women over 50 will break a bone because of osteoporosis. Hip fractures in particular carry serious consequences for independence and health.
• The process is silent - there are no symptoms until the first fracture.

HRT is genuinely protective here: the WHI trial showed fewer hip and vertebral fractures in women on hormone therapy, and guidelines recognize it as a valid option for preventing bone loss in the early postmenopausal years. Forgoing HRT does not doom your bones - but it removes one effective protection, and the replacement plan (strength training, calcium and vitamin D, not smoking, and a DEXA scan when recommended, with bone-specific medication if needed) has to actually happen rather than stay theoretical.

Early menopause: where not treating is the clearly riskier path

This is the one scenario where the evidence stops being balanced and points firmly one way. If menopause arrives before 45 (early menopause) or before 40 (premature ovarian insufficiency), your body faces many extra years without estrogen that it was built to expect.

Untreated, that is associated with:

• Substantially higher osteoporosis and fracture risk
• Higher cardiovascular disease risk and earlier cardiac events
• Higher risk of cognitive decline and dementia in some studies
• Higher all-cause mortality in long-term cohorts

For this group, guidelines - NICE, The Menopause Society, and others - actively recommend HRT until at least the average age of natural menopause (around 51), unless there is a specific contraindication. Here, hormone therapy is not symptom relief; it is replacing something missing years ahead of schedule. If this is you and you are untreated, this single section is worth a clinician conversation this month.

Your heart: the window that closes

Before menopause, women have notably lower heart disease rates than men; within a decade after it, the gap largely closes. Falling estrogen shifts cholesterol the wrong way, stiffens blood vessels, raises blood pressure, and moves fat storage to the abdomen - the American Heart Association describes the menopause transition as a time of accelerating cardiovascular risk.

The nuance from the timing hypothesis: started near menopause, HRT does not raise coronary risk and may modestly help; started late, it can harm. Two honest conclusions follow. First, no guideline recommends HRT solely to prevent heart disease - the evidence is not strong enough for that. Second, the decision window is real: a woman who defers the decision for 15 years has genuinely lost options. Either way, the non-negotiables are the unglamorous ones: blood pressure, lipids, blood sugar, exercise, and not smoking - with or without hormones.

Vaginal and urinary symptoms: the ones that only get worse

Hot flashes eventually fade for most women. Genitourinary syndrome of menopause (GSM) does not. Untreated, the thinning and drying of vaginal and urinary tissue tends to progress:

• Dryness and pain that can end comfortable sex entirely
• Recurrent urinary tract infections - which in older age can become genuinely dangerous
• Urinary urgency and incontinence that erode confidence and activity

The tragedy of GSM is that the safest hormone treatment in menopause care - local vaginal estrogen - treats it effectively with almost none of systemic HRT's risks, and most affected women never ask. Declining systemic HRT is one decision; leaving GSM untreated is a separate, unforced one.

Untreated symptoms: the cost nobody itemizes

Hot flashes last about 7 years on average - for 1 in 3 women, more than a decade. Untreated moderate-to-severe symptoms are not just uncomfortable:

• Sleep breaks first: night sweats and 3 a.m. waking, night after night, for years.
• Broken sleep drags down mood, patience, and thinking - perimenopause already carries an elevated risk of depression and anxiety, and sleep deprivation amplifies it.
• Brain fog worsens with poor sleep and frequent flashes; research links severe vasomotor symptoms to worse cardiovascular risk markers as well.
• The compound cost lands on work, relationships, and identity - a large share of women report menopause symptoms affecting their careers, and some leave jobs over it.

Suffering through it is survivable. But "it's natural" is not a reason to endure a treatable condition for seven years - we do not apply that logic to migraines or broken ankles. If it is disrupting your life, it deserves treatment - hormonal or otherwise.

The honest balance sheet

Declining to take HRT is entirely reasonable in many situations: mild symptoms, personal risk factors, personal preference. The point of this article is narrower - each benefit you decline needs a plan B:

1. Bones: strength training, calcium and vitamin D, DEXA screening, and bone medication if loss shows up.
2. Heart: the standard prevention toolkit, taken seriously from your 40s on.
3. GSM: vaginal estrogen or moisturizers - this one is close to a free win.
4. Hot flashes and sleep: non-hormonal options - fezolinetant, certain low-dose antidepressants, CBT - genuinely work.
5. Early menopause: talk to a clinician - this is the scenario where declining treatment carries the clearest documented harm.

How Femora helps

The "do nothing" path feels costless partly because nobody measures its cost. Femora makes it measurable: log your hot flashes, sleep, and mood with menopause mode, and the menopause symptom score turns your symptom burden into a number you can watch over time. If the number is low, that is real reassurance that skipping treatment is working for you. If it is high and climbing, that is the evidence that the untreated path is the one carrying the risk - and exactly what to show a clinician. Unsure where you are in the transition? Start with the perimenopause quiz.

The bigger picture

The question is not "is HRT risky?" - everything, including doing nothing, is risky. The question is which set of risks you would rather manage, with your symptoms, your history, and your alternatives on the table. Women deserve the whole ledger: the risks of hormone therapy on one page, and the risks of untreated estrogen loss on the other. Now you have both.

This is general information, not a substitute for advice from your own clinician. Download Femora to put numbers on your own ledger.